Organon Management

Management criteria checks 3/4

Organon's CEO is Kevin Ali, appointed in Jun 2021, has a tenure of 3.33 years. total yearly compensation is $14.83M, comprised of 8.4% salary and 91.6% bonuses, including company stock and options. directly owns 0.056% of the company’s shares, worth $2.73M. The average tenure of the management team and the board of directors is 3.3 years and 3.3 years respectively.

Key information

Kevin Ali

Chief executive officer

US$14.8m

Total compensation

CEO salary percentage8.4%
CEO tenure3.3yrs
CEO ownership0.06%
Management average tenure3.3yrs
Board average tenure3.3yrs

Recent management updates

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

May 29
Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Recent updates

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Sep 19

These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way

Sep 13
These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way

Organon & Co.: Cheap With Caveats

Aug 22

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Aug 09
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price

Aug 07
Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price

Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum

Jul 30

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

May 29
Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

May 10
Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

Four Reasons Why Organon Stock Is A Good Buy

May 07

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Apr 21
Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Organon Stock Is Still Worth A Look

Feb 24

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Feb 19
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Feb 16

Organon: What I'm Looking For In This 8% Yield In 2024

Jan 03

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Dec 19

Organon: It's Darkest Before The Dawn

Nov 30

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Nov 07

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Nov 05
Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Oct 04

6% Yield And Significantly Undervalued: A Closer Look At Organon

Sep 10

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Aug 10

Organon & Co.: A Tough Spot To Be In Right Now

Jul 16

Organon goes ex-dividend tomorrow

Feb 23

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 19
Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Is There Anything Organic Or Interesting About Organon?

Feb 07

Organon goes ex-dividend tomorrow

Nov 09

Organon's (NYSE:OGN) Dividend Will Be $0.28

Nov 08
Organon's (NYSE:OGN) Dividend Will Be $0.28

Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)

Nov 05
Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)

Organon: Thoughts Ahead Of Q3 Earnings

Oct 31

Organon: What Is The Recipe?

Aug 31

Oragenics announces early toxicology data for intranasal COVID-19 vaccine

Aug 24

Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod

Aug 17

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Aug 07
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

CEO Compensation Analysis

How has Kevin Ali's remuneration changed compared to Organon's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$15mUS$1m

US$1b

Sep 30 2023n/an/a

US$585m

Jun 30 2023n/an/a

US$754m

Mar 31 2023n/an/a

US$746m

Dec 31 2022US$14mUS$1m

US$917m

Sep 30 2022n/an/a

US$1b

Jun 30 2022n/an/a

US$1b

Mar 31 2022n/an/a

US$1b

Dec 31 2021US$19mUS$1m

US$1b

Compensation vs Market: Kevin's total compensation ($USD14.83M) is above average for companies of similar size in the US market ($USD8.11M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


CEO

Kevin Ali (64 yo)

3.3yrs

Tenure

US$14,832,272

Compensation

Mr. Kevin Ali is Chief Executive Officer and Director of Organon & Co. since June 2, 2021. Mr. Ali served as the President of Global Enterprise Portfolio Strategy at Merck & Co., Inc. from 2019 to 2021 and...


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Ali
CEO & Director3.3yrsUS$14.83m0.056%
$ 2.7m
Matthew Walsh
Executive VP & CFO3.3yrsUS$5.21m0.036%
$ 1.7m
Kirke Weaver
Executive VP1.8yrsUS$3.19m0.011%
$ 549.3k
Susanne Fiedler
Executive VP & Chief Commercial Officer3.8yrsUS$3.84m0.021%
$ 1.0m
Joseph Morrissey
Executive VP and Head of Manufacturing & Supply3.3yrsUS$3.74m0.017%
$ 807.2k
Rachel Stahler
Executive VP & Chief Information Officer3.3yrsno data0.019%
$ 944.9k
Jennifer Halchak
Head of Investor Relations3.8yrsno datano data
Susan O'Neal
Chief Ethics & Compliance Officerno datano datano data
Rebecca Edwards
Chief Communications Officerno datano datano data
Daniel Karp
Chief Business Development Officerno datano data0.0075%
$ 364.6k
Aaron Falcione
Executive VP & Chief Human Resources Officer3.3yrsno data0.013%
$ 614.8k
Vittorio Nisita
Executive VP & Head of Global Business Services3.3yrsno data0.0096%
$ 465.9k

3.3yrs

Average Tenure

56yo

Average Age

Experienced Management: OGN's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Ali
CEO & Director3.3yrsUS$14.83m0.056%
$ 2.7m
Carrie Cox
Independent Chairman of the Board3.3yrsUS$450.00kno data
Robert Essner
Independent Director3.3yrsUS$335.00kno data
Rochelle Lazarus
Independent Director3.3yrsUS$320.00k0.00025%
$ 12.1k
Martha McGarry
Independent Director3.3yrsUS$320.00kno data
R. Alan Ezekowitz
Independent Director3.3yrsUS$330.00kno data
Helene Gayle
Independent Director3.3yrsUS$320.00kno data
Shalini Sharp
Independent Director3.3yrsUS$345.00k0%
$ 0
Philip Ozuah
Independent Director3.3yrsUS$320.00kno data
Cynthia Patton
Independent Director3.3yrsUS$330.00kno data
Grace Whiteford
Independent Director3.3yrsUS$320.00k0%
$ 0
Deborah Leone
Independent Director3.3yrsUS$330.00k0%
$ 0

3.3yrs

Average Tenure

64yo

Average Age

Experienced Board: OGN's board of directors are considered experienced (3.3 years average tenure).